Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company, not an exchange-traded fund, developing viral immunotherapies for cancer. The question facing investors is whether the stock can reach a CADL stock price target of $23 — a level that reflects a far more optimistic view than where shares recently traded.
Reviewing eight current, individually attributed analyst price targets yields a calculated average of about $23.13, rounded to a central target of $23. The approximate range spans $16 to $30. On the cautious end, LifeSci Capital maintains a $16 target (August 14, 2026) and Bank of America Securities holds a $18 target (October 1, 2026). The more bullish targets include Stifel at $22, H.C. Wainwright at $23 (November 9, 2026), Canaccord Genuity and Jefferies at $25 each, Citi at $26, and Cantor Fitzgerald at $30 (initiated April 20, 2026).
Notably, Bank of America upgraded the stock from Neutral to Buy in September 2026 and raised its target from $12 to $18, while Jefferies initiated coverage with a Buy and a $25 target in October 2026. The reasoning behind bullish views centers on aglatimagene besadenovec, the lead candidate that produced positive Phase 3 results in localized prostate cancer. Cautious analysts emphasize that the company is pre-revenue and that regulatory milestones, not near-term earnings, will determine value. The $23 figure should be read as a calculated average of these opinions, not a guaranteed destination.
With shares recently near $8.39, reaching $23 would require an advance of roughly 174% — a very large move. The path is heavily binary and tied to regulatory execution. In its third-quarter 2026 update, Candel said it now plans to submit its BLA for aglatimagene in prostate cancer in mid-2027, citing timelines tied to assay refinement, and shares fell further in extended trading. The company reported a net loss of roughly $38.9 million for the June 2026 quarter and remains pre-revenue, with a 52-week range of $4.35 to $14.00. Reaching $23 would require not only successful regulatory progress but also a substantial re-rating of a development-stage biotech whose market capitalization is around $640 million to $715 million.
The core support is clinical. Aglatimagene's pivotal Phase 3 trial in localized prostate cancer was conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), and results were published in The Lancet Oncology. The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy designations. A royalty purchase agreement announced in February 2026 with funds managed by RTW Investments provides up to $100 million upon FDA marketing approval, offering non-dilutive validation. The balance sheet also provides runway: roughly $201.6 million in cash against about $49.5 million in debt, a net cash position near $152 million. Positive data at SITC 2026 and a "Strong Buy" consensus reflect continued analyst conviction in the platform's long-term potential.
Regulatory risk is the dominant obstacle. The shift in the BLA submission timeline to mid-2027 means the company's most important catalyst has moved further out, extending the period of cash burn before any potential commercial revenue. Candel is pre-revenue, with a trailing net loss near $88.5 million and diluted EPS (earnings per share) around -$1.46. The company has also filed to sell up to $50 million of stock through an at-the-market program, a source of shareholder dilution. Elevated short interest — roughly 17% of shares outstanding and about 22% of float — signals substantial skepticism, and any additional regulatory setback could trigger sharp repricing.
The stock's 52-week range of $4.35 to $14.00 frames the debate. The 200-day moving average near $8.37 is a key near-term reference, while the 52-week high near $14.00 acts as a notable resistance zone. Beyond that, the $15 and $20 levels represent psychological milestones on any path toward $23. A sustained move toward the target would require the stock to first reclaim and hold above prior highs, a tall order given recent downward pressure following the BLA timeline update.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual assumptions differ. Investors should monitor the BLA submission timeline and any FDA feedback, updated Phase 3 and biomarker data from medical meetings, cash position and financing activity, analyst target revisions, and short-interest trends. Regulatory decisions and clinical readouts — not quarterly earnings — are the primary value drivers for this pre-commercial company.
For traders tracking volatile development-stage names like Candel, AI Daily Buy/Sell Signals offers a data-driven way to stay oriented. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than replacing fundamental research, it helps traders discover opportunities, monitor existing positions, and spot changing trends more efficiently — a useful complement when a single news item can move a small-cap biotech sharply.
The $23 central target — an average of eight analyst price targets ranging from $16 to $30 — implies a roughly 174% advance from recent levels, a very large move that hinges almost entirely on regulatory execution for aglatimagene. Bullish cases lean on positive Phase 3 data, FDA designations, and the RTW royalty agreement, while bearish cases point to the BLA delay to mid-2027, persistent losses, dilution, and heavy short interest. The wide analyst range underscores genuine uncertainty. Whether CADL can reach $23 depends less on near-term trading than on whether the company clears its next regulatory milestones without further delays.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CADL has been loosely correlated with NTLA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CADL jumps, then NTLA could also see price increases.
| Ticker / NAME | Correlation To CADL | 1D Price Change % | ||
|---|---|---|---|---|
| CADL | 100% | -26.10% | ||
| NTLA - CADL | 52% Loosely correlated | -8.06% | ||
| EDIT - CADL | 51% Loosely correlated | +1.40% | ||
| FDMT - CADL | 48% Loosely correlated | +0.95% | ||
| SANA - CADL | 48% Loosely correlated | +0.50% | ||
| BEAM - CADL | 46% Loosely correlated | -4.99% | ||
More | ||||